Sheel Biotech Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Sheel Biotech Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹63
Per ShareLot Size
2000 Shares
Minimum Investment
₹1,26,000
Issue Size
₹34.02 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.18%
QIB Quota
49.73%
NII Quota
15.09%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Sheel Biotech Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
96.09%
Promoter Holding (Post-Issue)
71.26%
Issue Type
Book Building - SME
ISIN
INE0YJV01017
About the Company
Our Company is engaged in the business of growing, developing, processing, and supplying a wide range of plants for field crops, fruits, vegetables, and ornamental plants through tissue culture and organic farming. We manufacture and maintain greenhouses, offer services to farmers and provide training through Farmer Producer Organizations (FPOs). Additionally, we deliver green landscaping services to both government and private sectors.
Industry Overview
The tissue culture technique is being utilised for micropropagation and commercialisation of agricultural crops, mass multiplication of desired plant variety, germplasm protection, development of newer cultivars with specific desirable traits, raising disease free plants and proliferation of elite and endangered plants. With the help of micropropagation techniques, the Indian plant tissue culture industry has become successful in various sectors such as agriculture, medicine, and forestry. Improved media formulations, bioreactors, automation and other technologies have enhanced the efficiency and productivity of tissue culture processes. Implementation of automated controls in bioreactors minimizes manual intervention and increases multiplication rates. Due to advancements in plant biotechnology and genetics, there is now potential to produce disease resistant and higher yielding crop varieties through plant tissue culture methods. Researchers are developing innovative methods to genetically modify plant cells to make them resistant to herbicides, insects, fungi, viruses and other stresses. This offer possibilities to customize crop varieties suitable for different agro-climatic conditions.
Company History
Our Company, Sheel Biotech Limited (hereinafter referred to as "SBL" or "Our Company") was incorporated as a private limited company with the name of "Sheel Biotech Private Limited" under the Companies Act, 1956 vide certificate of incorporation dated November 26, 1991, issued by that time Registrar of Companies, Delhi & Haryana, bearing Registration No. 046531. Further, our company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of our Company at the Extra- Ordinary General Meeting held on December 30, 1991 & name of our Company changed from "Sheel Biotech Private Limited" to "Sheel Biotech Limited" & Registrar of Companies, Delhi & Haryana has issued a new certificate of incorporation consequent upon conversion dated April 02, 1992, bearing CIN: U24239DL1991PLC046531.
Growth Strategy
- Collaboration with Dutch technology.
- Northern Region 2nd biggest tissue culture lab.
- Dedicated team for procuring government tenders.
- Green house facilities which protects the plants from hardening.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of 54,00,000 equity shares of Rs. 10/- each ("Equity Shares") of Sheel Biotech Limited ("S B L" or The "Company") for cash at a price of Rs. 63/- per equity share (The "Issue Price"), aggregating to Rs. 34.02 crores ("The Offer"). Out of the issue 2,72,000 equity shares aggregating to Rs. 1.71 crores will be reserved for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. issue of 51,28,000 equity shares of face value of Rs. 10.00/- each at an issue price of Rs. 63/- per equity share aggregating to Rs. 32.31 crores is hereinafter referred to as the "Net Issue". The issue and the net issue will constitute 26.53% and 25.20%, respectively of the post issue paid up equity share capital of the Company. Price Band: Rs. 59/- to Rs. 63/- for equity share of face value of Rs. 10 each. The floor price is 5.90 times times the face value and cap price is 6.30 times of the face value of the equity shares. Bids can made for a minimum of 4,000 equity shares and in multiples of 2,000 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Our ability to capitalize the opportunities and growth in the Tissue Culture industry.
- Promotion of Tissue Culture industry by the Government of India.
- Cordial relations with our clients.
- The company depends on government tenders for its revenue of operations. Any unavailability or any failures to secure these tenders in the future may adversely affect the company's business operations and financial conditions.
- One of the company's business segment Tissue culture demands the highest level of precautions in quality, storage, and temperature management. Any negligence in these areas can significantly affect its business outcomes.
- The company uses the proper techniques in the whole tissue culture process. Any Ineffective sterilization of tools and media can lead to contamination, which would adversely affect the entire culture.
- The company's business is subject to seasonal fluctuations that could result in delays or disruptions to its operations during the critical periods of the company's projects and cause severe damage to its premises and equipments.
- The Company is involved in certain legal proceedings/litigations. Any adverse decision in such proceedings may render us/them liable to penalties and may adversely affect ist business and result of operations.